Experimental Therapeutics Group Archives

RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…

PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models

Published open access in Genome Medicine, results of a study led by VHIO’s Experimental Therapeutics Group further support the use…

Collage Dra. Judith Balmaña delante de pantall de ordenador y Dra. Violeta Serra en laboratorio

Analysis of DNA repair deficiency in breast and ovarian tumours with pathogenic germline variants in the RAD51C or RAD51D genes could be useful for steering targeted therapy

The analysis of homologous recombination DNA repair in primary breast and ovarian tumours in patients with pathogenic germline variants in…

‘Double strike’ strategy slows growth of drug-resistant breast cancer

Laboratory tests with mice reveal ‘exciting’ new strategy that could transform triple-negative breast cancer into a manageable disease Researchers at…

Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients…